XTNT Xtant Medical Holdings, Inc.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1453593 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.4%
TTM net income YoY-1,014.2%
TTM EPS YoY-1,200.0%
Revenue 3-yr CAGR8.6%
Net income 3-yr CAGR—
Margins
Gross margin56.4%
Operating margin-16.0%
Net margin-15.9%
FCF margin-6.1%
EBITDA margin-12.6%
Returns
ROE-36.5%
ROA-17.6%
ROIC (approx.)-26.2%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets50.5%
Debt / equity0.27x
Current ratio2.00x
Interest coverage-6.56x
Cash quality & payout
Operating cash flow / net income0.31x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $133.93M | $117.27M |
| Cost of revenue | $49.65M | $49.05M |
| Gross profit | $84.27M | $68.22M |
| R&D expense | $2.10M | $2.38M |
| SG&A expense | $29.38M | $28.69M |
| Operating income | $7.28M | -$12.07M |
| Interest expense | $3.67M | $4.16M |
| Pretax income | $7.00M | -$16.26M |
| Income tax | $2.03M | $187,000 |
| Net income | $4.97M | -$16.45M |
| EBITDA | $12.51M | -$7.85M |
| EPS (basic) | 0.04 | -0.12 |
| EPS (diluted) | 0.03 | -0.12 |
| Weighted avg. shares (diluted) | 150.04M | 133.67M |
| Balance sheet | ||
| Cash & equivalents | $17.05M | $6.20M |
| Receivables | $17.80M | $20.66M |
| Inventory | $30.26M | $38.63M |
| Current assets | $78.25M | $67.12M |
| PP&E, net | $6.20M | $10.13M |
| Goodwill | $6.07M | $7.30M |
| Intangibles | $299,000 | $8.36M |
| Total assets | $94.14M | $93.84M |
| Current liabilities | $29.48M | $28.58M |
| Short-term debt | $3.50M | — |
| Long-term debt | $11.03M | $22.04M |
| Total debt | $14.53M | $22.04M |
| Total liabilities | $43.19M | $50.87M |
| Shareholders' equity | $50.95M | $42.96M |
| Net debt | -$2.53M | $15.84M |
| Shares outstanding | 140.04M | 139.05M |
| Cash flow statement | ||
| Operating cash flow | $12.55M | -$11.90M |
| Capital expenditure | $2.38M | $4.11M |
| Free cash flow | $10.16M | -$16.01M |
| Investing cash flow | $7.90M | -$3.73M |
| Financing cash flow | -$9.57M | $16.07M |
| Depreciation & amortization | $5.22M | $4.22M |
| Stock-based compensation | $2.89M | $4.12M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.